has function has role vaccinated in route immunizes against disease immunizes recipient urinary bladder cancer Homo sapiens therapeutic vaccine function vaccine in clinical trial role intradermal route bladder cancer vaccine ags-003-bld vaccine 959 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6363 Hayleigh Kahn cancer vaccine NCT: https://clinicaltrials.gov/study/NCT02944357 Jie Zheng Gene name: CD40LG 6363 NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C129522 A cancer vaccine composed of autologous, mature dendritic cells (DCs) are electroporated with in vitro transcribed (IVT) RNAs encoding for a synthetic form of T-cell protein CD40 ligand (CD40L) and IVT RNA encoding for autologous tumor-associated antigens (TAAs) derived from patient-specific bladder cell carcinoma (BCC) cells, with potential immunostimulatory and antineoplastic activities. The RNA is translated and processed, and BCC-specific antigenic peptides are subsequently presented via major histocompatibility complex (MHC) Class I molecules on the DCs surface. The MHC-presented peptides interact with and activate CD8-positive T-cells, which elicits a highly specific cytotoxic T-cell (CTL) response against tumor cells expressing the patient-specific BCC TAAs. The signal cascade initiated by expression of the co-stimulatory molecule CD40L results in the secretion of the inflammatory cytokine IL-12, which further stimulates CTLs. The vaccine can be used in combination with gemcitabine hydrochloride and cisplatin which stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading, while the vaccine helps the body build an effective immune response to kill tumor cells. In combination, they may make the tumor smaller and reduce the amount of tissue that needs to be removed by surgery in patients with bladder cancer. therapeutic cancer vaccine whole cell cancer vaccine